For in vitro experiments, dasatinib inhibited LIMK activity by negatively regulating the phosphorylation of the LIMK1 substrate, cofilin, which resulted in growth inhibition, apoptosis and cell cycle arrest in lung cancer cell lines that were highly expressed LIMK1. Here, LIMK1 is linked to lung carcinoma.